Actinobacillus actinomycetemcomitans is a Gram-negative capnophilic rod and the etiological agent of localized aggressive periodontitis. The genome-wide survey of A. actinomycetemcomitans using in vivo induced antigen technology (IVIAT) has previously resulted in the discovery of antigenic determinants expressed specifically in diseased patients. The present study evaluated the potential of these antigens as putative disease markers, and investigating their contribution to the pathogenesis of the microorganism. Sera from patients had a significantly greater antibody titer than sera from healthy controls against six antigens, which supports the in vivo expression of these antigens, and suggests their usefulness as disease markers. A. actinomycetemcomitans invasion of epithelium-derived HeLa cells resulted in the induction of all three genes tested, as evidenced by real-time PCR. Isogenic mutants of these three genes were constructed and the adhesion and intracellular survival of the mutants was assayed in a competition assay with the wild-type strain. A significant defect in the intracellular survival of two of these mutant strains (orf1402 and orf859) was found. This defect could not be attributed to an adhesion defect. In contrast, a mutation in vapA, a homologue of a novel putative transcriptional regulator, out-competed the wild-type strain in the same assay. The virulent phenotype was restored for a mutant strain in orf859 upon complementation. This data provided new insight into the pathogenic personality of A. actinomycetemcomitans in vivo and supported the use of HeLa cells as a valid in vitro host-pathogen interactions model for that microorganism. IVIAT is applicable to most pathogens and will undoubtedly lead to the discovery of novel therapies, antibiotics and diagnostic tools.
Introduction
Actinobacillus actinomycetemcomitans is the etiological agent of localized aggressive periodontitis (LAP) (reviewed in [1] ). The pathogenicity of A. actinomycetemcomitans is multifaceted and the pathophysiology of the infection is influenced by both microbial and host determinants. A number of putative virulence factors have been described for this microorganism (reviewed in [2] ). A. actinomycetemcomitans invades epithelial tissues and produces several biologically active substances that collectively could be involved in disease causation and persistence. The identity, relevance and mechanism of action of the virulence factors that actually provide a selective advantage to the organism in the oral cavity of diseased patients are still unclear. At present, radiographic evidence of bone loss is the only available diagnostic tool for Actinobacillus-related periodontal diseases. However, this method's lack of sensitivity means that by the time disease is detected, it has progressed to the point where irreparable damage has occurred. As is the case with a number of other human pathogens, current detection methods cannot distinguish between the colonization state versus the active and destructive disease state.
It is generally accepted that genes of a pathogen that are specifically expressed during infection are likely to be important to pathogenicity. Numerous technologies such as in vivo expression technology (IVET), differential fluorescence induction (DFI) and signature-tagged mutagenesis (STM) have been developed over the past decade to identify genes of pathogens that are specifically expressed during an actual infectious process (reviewed in [3] ). Those methods have unfortunately not been useful for identifying in vivo induced genes of A. actinomycetemcomitans since no well-validated and widely accepted animal model was available until very recently. This initially led us to develop an alternative strategy, in vivo induced antigen technology (IVIAT), to identify genes of this microorganism specifically induced during an actual human infection [4] . IVIAT avoids the use of animal models by using serum from patients who have experienced disease caused by the pathogen under study. A. actinomycetemcomitans was the prototype organism for the development of IVIAT and has been since used to study other pathogens including Candida albicans [5] , Vibrio cholera [6] , Mycobacterium tuberculosis [7] and V. vulnificus [8] .
We previously reported that the screening of the entire A. actinomycetemcomitans genome with IVIAT resulted in the discovery of 116 in vivo induced antigens, which fell in diverse functional categories based on sequence analysis [9] . The purpose of the present paper is to report the identity and further characterize the first nine of 116 antigens that were found with IVIAT. Furthermore, this is the first report that investigates antigens found with IVIAT for their potential in diagnostic applications. This study finally investigates an existing model of infection as a rational platform to study the contribution of those proteins in the pathogenesis of the organism.
Materials and methods

Bacterial strains and growth conditions
The bacterial strains used are listed in Table 1 , and were grown using standard methods [10] . A. actinomycetemcomitans strains VT1169 and strain HK1651 are phenotypically smooth.
Western-blot and densitometric analysis
A. actinomycetemcomitans genes cloned in pET30a b, c were transformed in Escherichia coli BL21(DE3) and protein production was induced with 1 mM IPTG according to the manufacturer's protocol (Novagen, Madison, WI). Western analysis [11] was performed using individual healthy control sera and individual localized aggressive periodontitis patients' sera at a 1:20,000 dilution and a peroxidase-conjugated goat antihuman anti-serum (ICN/Cappel, Aurora, OH) at a 1:10,000 dilution. The patients' sera were obtained from existing sera banks by Dr. M. Taubman (Forsyth Dental Center, Boston, MA) and Dr. W.P. McArthur (University of Florida, Gainesville, FL) from LAP patients identified by family history and clinical, microbiological and radiographic examinations. Microbiological and immunological analyses indicated a role for A. actinomycetemcomitans as the etiologic agent in each of these cases. These sera were tested individually by a modified ELISA procedure [15] using French-press disrupted cell extracts of A. actinomycetemcomitans strain HK1651 to verify that they retained their reactivity. Healthy control sera were obtained without identifiers from blood banks since the prevalence of LAP is relatively low (less than 1%). Reactive proteins were detected using chemiluminescence (ECL kit and hyperfilm, Amersham Pharmacia Biotech, Piscataway, NJ). Specific density on the film was compared using the Quantity One software (BioRad, Hercules, CA) and analyzed by Student's t-test. The protocol was reviewed and approved by an appropriate Institutional Review Board.
Isogenic mutation construction
Mutations were constructed using an allelic replacement technique resulting in an insertional inactivation of the selected genes with a Spec-resistance cassette. Internal fragments of the genes of interest were PCR amplified from genomic DNA using the following primers: lktB-
0 -TTGAATTCCGCAATGCTTCTGC-CATCAC. The resulting amplicons were gel-purified and ligated into the suicide vector pVT1460 at the PstI site [10] . Inverse-PCR mutagenesis with the primers described below was then used to delete a portion of the cloned gene:
0 -GCATC-GGAAGATTTGACGCA. Invert-PCR amplicons were blunt-end ligated to the kinase-treated spectinomycin cassette aad9 isolated by PCR from the vector pPK1 [12] . In the mutant strain JMS02, the lktA gene was cloned in pVT1460 and disrupted by direct insertion of the spectinomycin cassette aad9 into a unique NcoI restriction enzyme site. Each construct was confirmed by restriction mapping and by PCR. All constructs were ultimately transformed into E. coli SM10 (k pir) for conjugation with A. actinomycetemcomitans and to select for the correct isogenic mutant upon resolution of the merodiploid [10] .
Adhesion, invasion, competitive index (CI) and complementation assays
The adhesion, invasion and CI assays were carried out using a modification of the quantitative KB (HeLa) cells invasion assay [13] at a multiplicity of infection (MOI) of 2500:1 bacteria to HeLa cells. For the CI determination, a 1:1 ratio was obtained by mixing equal volumes of mutant and wild-type bacterial cultures standardized to an optical density of 0.2 at 495 nm. After incubation with gentamicin (100 lg ml À1 ) to kill extra cellular bacteria, cells from one set of wells were lysed and plated. The ratio of mutant CFU to wild-type CFU was calculated by picking 100 colonies pre-and post-infection, and inoculating solid media with or without spectinomycin, the genetic marker carried only by the mutant strains. The CI was determined as the recovered ratio of mutant CFU to wild-type CFU, divided by the inoculated ratio of mutant CFU to wildtype CFU. The CI was expressed as the mean and standard deviation of experiments done in triplicate [14] . The complementation of one (Dorf 1402) of the three mutant was attempted as described previously [10] using a DNA fragment containing the entire coding sequences of orf1402 and approximately 500 bp upstream of the putative translation initiation start codon, to include the native promoter sequences of orf1402. A Student's t-test was used to evaluate the statistical significance of the observed differences.
Real-time PCR
Bacterial gene expression was tested by real-time PCR on bacteria grown under standard laboratory conditions and compared to bacteria recovered from infected HeLa cells. Bacteria were sampled at the time of infection and after 2 h post-infection. An aliquot of the infected cells was lysed and used to measure colonyforming units (CFUs). The total RNA was extracted and purified with the RNeasy mini kit and DNAseItreated following the manufacturer's recommendations (Qiagen Inc., Valencia, CA). The amount of template in the PCR was normalized based on the recovered CFUs in the infected cells. cDNA was reverse-transcribed from a 50 ng aliquot of total RNA, using random hexamers from the SUPERSCRIPT II 1st Strand Synthesis Kit (Invitrogen, CA) according to the manufacturer's instructions, which was then followed by the real-time PCR reaction, carried out using the Bio-Rad iQ SYBRgreen super mix, in duplicate independent experiments and following the manufacturer's protocols. The universal A. actinomycetemcomitans rRNA primers were used in the reaction as internal controls: RT-16SrRNA-Forward, 5 0 -TCGGTATTGAGGAAGGTTGG; RT16SrRNA-Reverse, 5 0 -CTGCTGGCACGGAGTTAG. The following genes specific primer sets were used for the PCR amplification: RTorf1402-Forward 5 0 -CTGCGTCCATTCCTGATACC, and RTorf1402-Re- comparing the threshold cycle number differences to a standard curve.
Results and discussion
IVIAT antigens as diagnostic tools
A subset of nine of the 116 in vivo induced genes identified using IVIAT were randomly selected and further characterized in this study. Only limited information was available from the literature and databases with respect to the precise role of these genes in pathogenesis (Table 2) . It was clear, however, that these genes were putatively involved in a variety of functions, such as regulation, metabolism, pathogenesis and adaptation. Since A. actinomycetemcomitants is also a member of the human indigenous flora, it was expected that most subjects would have circulating antibodies directed against proteins of A. actinomycetemcomitans associated with persistent colonization. With the onset of periodontitis, and in response to the changing environment or bacterial load at the site of infection, we speculated that new bacterial proteins would be produced and that these products could be associated with the initiation and progression of the disease state. It is this latter group of proteins that were particularly interesting from the standpoint of their potential to serve as targets for diagnostic and therapeutics strategies. A Western blotting approach was thus used to determine if sera from periodontitis patients possessed higher reactivity with the selected IVIAT proteins than sera from control patients. A significant titer was found in healthy controls for all antigens tested (Fig. 1) . Densitometric and statistical analyses (Student's t-test) of reactive bands appearing in the Western blot demonstrated that patient sera had, on average, significantly ðp < 0:05Þ greater reactivity with six of the proteins (Fig. 1 ) as compared to sera from healthy controls. This suggests that the expression of those six antigens may be particular to the disease state.
This data also suggests that those six antigens are broadly immunogenic and show some patient-to-patient differences in their overall level of reactivity (Fig. 1) . The other three antigens, which showed a level of reactivity similar ðp > 0:05Þ to the level of reactivity in control subjects, may have a role in colonization rather than in disease causation per se. Three of the putative disease markers were chosen for further analysis.
Gene expression profile analysis
We had previously demonstrated that one of these antigens, the product of orf859, was specifically expressed by A. actinomycetemcomitans in dental plaque of LAP patients using immunofluorescence [4, 15] . Although immonofluorescence presented the most direct and definitive demonstration of in vivo induction of orf859, it was too cumbersome of an approach to use for the routine validation of other IVIAT-identified antigens, or to verify their induction under different environmental conditions. We thus used real-time PCR for this purpose, which had the advantages of being rapid, semi-quantitative and convenient. We also used epithelial HeLa cells as a model of infection since these have been used extensively in the literature [13] . Controls for this experiment included lktA encoding the well-studied leucotoxin gene, which is expressed during in vitro growth of the pathogen [16] . Under the infection conditions used, virtually every HeLa cell was infected at a level of 1-5 CFU per HeLa cell, or 0.1-0.5% of the inoculum, which is consistent with previously reported data [17] . The template amount used in the assay was normalized using the total count of viable bacteria (CFU) as a reference point, and done in duplicate in at least two independent experiments. The transcription of orf1402, vapA and orf859 were significantly ðp < 0:05Þ increased in HeLa cells as compared to bacteria grown extracellularly. For these three transcripts, the induction level was fourfold, fivefold, and 19-fold, respectively (data not shown). Expression of lktA was not significantly ðp ¼ 0:3Þ different during invasion of HeLa cells compared to in vitro grown cells. Interestingly, the expression the rRNA was also induced 11-fold intracellularly (data not shown), which is consistent with the increased growth rate observed by others [2] . This precluded the use of that commonly used control as a basis for RT-PCR quantification.
Altogether, the gene induction profiles presented here suggested that the three IVIAT genes characterized are in fact regulated by environmental cues found intracellularly in HeLa epithelial cells. This provided additional support for the use of HeLa cells as a valuable model of A. actinomycetemcomitans infection, and suggested that some of the environmental cues are commonly found in dental plaque and in epithelial cells. The specific environmental cues that trigger the expression of these genes are under investigation.
Mutant analysis and complementation
With the confidence that all three genes under study were induced intracellularly in HeLa cells, a mutant analysis approach was adopted to investigate the relative importance of these gene products on the intracellular survival of the pathogen. Isogenic mutations of orf1402, vapA and orf859 were therefore made by allelic replacement. Growth rate, colony morphology, smooth phenotype and clumping in liquid culture were unaltered during cultivation in vitro of the mutant strains (data not shown). As shown in Fig. 2 , the constitutive expression of the leucotoxin LktA intracellularly did not affect the viability of the host cell, and a mutant in lktA was not impaired in its ability to thrive in the intracellular environment of a HeLa cell. This toxin is best known for its extracellular interactions with neutrophiles and macrophages. Another control for this experiment was strain JMS01 (orf1250). This recombinant strain is a merodiploid that contains the antibiotic resistance marker used in mutation construction, and does not possess any known genetic defects. As expected, this control showed no difference relative to the wild-type strain with regard to adhesion, invasion, and/or persistence in HeLa cells. This control further demonstrated that the presence of the antibiotic resistance marker used in mutation construction did not affect the results obtained. The adherence of the mutant strains to HeLa cells, their invasion into HeLa cells and their intracellular persistence was analyzed using a competitive invasion assay. None of the mutants showed a detectable change in adhesion to HeLa cells relative to the wildtype strain (Fig. 2) . In contrast, two of the mutants, JMS04 (orf1402) and JMS05 (orf859), showed a significant ðp < 0:05Þ decrease, and one mutant JMS03 (vapA) a significant ðp < 0:05Þ increase in invasion and/ or intracellular survival relative to the wild-type strain, based on their CI (Fig. 2) . These results could not be attributed to differences in the initial adhesion to HeLa cells. This suggested that the in vivo induced genes orf1402 and orf859 express products that are important to the invasion or intracellular survival of A. actinomycetemcomitans. There are precedents for this observation in other pathogens such as Salmonella typhimurium ( [18, 19] and M. tuberculosis [20, 21] . No polarity issue was anticipated since the above described genes were part of monocystronic operons based on sequence analysis, or the last gene of a polycystronic operon for orf859. As shown in Fig. 2 , one of the two mutants (orf1402) was nevertheless complemented in trans and Fig. 2 . CI assay. HeLa cells were infected with an equal number of A. actinomycetemcomitans VT1169 and individual isogenic mutant or complemented strain (ratio 1:1). The adhesion was measured after 15 min of infection. The intracellular survival and complementation were measured after 2 h of infection. The ratio of mutant CFU to wild-type CFU was calculated. The CI was determined as the recovered ratio of mutant CFU to wild-type CFU, divided by the inoculated ratio of mutant CFU to wild-type CFU, and was expressed as the mean and standard deviation of experiments done in triplicate. Significant statistical variations (Student's t-test at p < 0:05) are highlighted with a (*). JMS01 is a merodyploid that contains two functional copies of orf1250 and was used as a negative control for the possible pleiotropic effect associated to the expression of the spectinomycine-resistance marker in this system. resulted in the restoration of the virulent phenotype as compared to the wild-type strain.
Unexpectedly, the strain JMS03 mutated in vapA outcompeted the wild-type strain in the HeLa cell model. Homologues of this gene have been studied in some detail in Dichelobacter nodosus (formerly Bacteroides nodosus) and Rhodococcus equi. The vap region is associated with virulence by genotypic association in both organisms. Their precise role in virulence has not yet been described [22] [23] [24] . Interestingly, the vapA homologue has significant homology to a number of DNAbinding domains of E. coli repressors including LacR, Cro434, and C1 (data not shown). It seems likely that if vapA acts as a transcriptional regulator in A. actinomycetemcomitans, as suggested by sequence analysis, the observed increase in competitiveness of the mutant may be explained by the down-stream regulation of gene(s) or operon(s) that confer a selective advantage to A. actinomycetemcomitans in HeLa cells. It has been reported that A. actinomycetemcomitans has a doubling time of approximately 150 min under laboratory conditions, and that this growth rate increases intracellularly to 20 min by an unknown mechanism [2] . The induction within HeLa cells of a bacterial factor that would result in the increase of the growth rate would conceivably allow this organism to outcompete the wildtype strain. Experiments, including direct functional analysis, are underway to explore this hypothesis.
The genes characterized in this study can rationally be studied by conventional techniques with the a priori confidence of their relevance in human infections. We propose that IVIAT could in the future be used to validate other in vitro systems, cell lines or animal models of infection by identifying those models that reproduce the same bacterial gene expression pattern as seen with IVIAT in human infections. Undoubtedly, the use of IVIAT will contribute to our understanding of the virulence of A. actinomycetemcomitans and a number of other pathogens. The data reported here support the relevance of the technique and present the basis to further characterize the genes discovered to date. Additional work will be needed to investigate the precise function of these genes and to reveal the nature of their relationship with the host. It is expected that IVIAT will precipitate the development of novel and rational therapies, diagnostic tools, and antibiotics.
